INTRODUCTION: Activation of renal sympathetic nerves is associated with the development of hypertension. Catheter-based renal sympathetic denervation with radiofrequency energy ablation is a new promising treatment option for resistant hypertension. We here report the first Danish experiences and results with this technique. MATERIAL AND METHODS: Nine patients with resistant hypertension and a day-time 24-hour ambulatory blood pressure (BP) of 152/89 mmHg ± 10/10 (standard deviation) mmHg despite treatment with 5.4 ± 1.4 anti-hypertensive drugs underwent catheter-based renal sympathetic denervation with the Symplicity catheter. RESULTS: No periprocedural complications or adverse events during follow-up were observed. Seven patients received complete ablation and two patients only partial ablation. Five patients responded to the treatment with a reduction in day-time 24-hour ambulatory BP from 158/94 ± 13/9 mmHg to 139/82 ± 10/8 mmHg (p < 0.05) at the one month follow-up and a reduction in the number of anti-hypertensive drugs from 5.4 ± 1.6 to 3.4 ± 0.9 (p < 0.05). BP in the remaining four patients was not significantly changed and antihypertensive therapy was not changed. CONCLUSION: Catheter-based renal sympathetic denervation is a feasible and in several cases also effective treatment option for patients with resistant hypertension. Adequately designed controlled trials are needed to assess the long-term safety and the full potential of this treatment.
INTRODUCTION: Activation of renal sympathetic nerves is associated with the development of hypertension. Catheter-based renal sympathetic denervation with radiofrequency energy ablation is a new promising treatment option for resistant hypertension. We here report the first Danish experiences and results with this technique. MATERIAL AND METHODS: Nine patients with resistant hypertension and a day-time 24-hour ambulatory blood pressure (BP) of 152/89 mmHg ± 10/10 (standard deviation) mmHg despite treatment with 5.4 ± 1.4 anti-hypertensive drugs underwent catheter-based renal sympathetic denervation with the Symplicity catheter. RESULTS: No periprocedural complications or adverse events during follow-up were observed. Seven patients received complete ablation and two patients only partial ablation. Five patients responded to the treatment with a reduction in day-time 24-hour ambulatory BP from 158/94 ± 13/9 mmHg to 139/82 ± 10/8 mmHg (p < 0.05) at the one month follow-up and a reduction in the number of anti-hypertensive drugs from 5.4 ± 1.6 to 3.4 ± 0.9 (p < 0.05). BP in the remaining four patients was not significantly changed and antihypertensive therapy was not changed. CONCLUSION: Catheter-based renal sympathetic denervation is a feasible and in several cases also effective treatment option for patients with resistant hypertension. Adequately designed controlled trials are needed to assess the long-term safety and the full potential of this treatment.
Authors: Lisette E G Hubens; Willemien L Verloop; Jaap A Joles; Peter J Blankestijn; Michiel Voskuil Journal: Curr Hypertens Rep Date: 2013-08 Impact factor: 5.369
Authors: Erin L O'Callaghan; Fiona D McBryde; Amy E Burchell; Laura E K Ratcliffe; Liviu Nicolae; Ivor Gillbe; Derek Carr; Emma C Hart; Angus K Nightingale; Nikunj K Patel; Julian F R Paton Journal: Curr Hypertens Rep Date: 2014-11 Impact factor: 5.369
Authors: Yutang Wang; Tam N Dinh; Alexander Nield; Smriti M Krishna; Kate Denton; Jonathan Golledge Journal: Front Physiol Date: 2017-04-13 Impact factor: 4.566
Authors: Hitesh C Patel; Carl Hayward; Vassilis Vassiliou; Ketna Patel; James P Howard; Carlo Di Mario Journal: Integr Blood Press Control Date: 2015-12-03
Authors: Ole N Mathiassen; Henrik Vase; Jesper N Bech; Kent L Christensen; Niels H Buus; Anne P Schroeder; Ole Lederballe; Hans Rickers; Ulla Kampmann; Per L Poulsen; Klavs W Hansen; Hans E Btker; Christian D Peters; Morten Engholm; Jannik B Bertelsen; Jens F Lassen; Sten Langfeldt; Gratien Andersen; Erling B Pedersen; Anne Kaltoft Journal: J Hypertens Date: 2016-08 Impact factor: 4.844